Computationally guided inhibition of the HIF-1α–CBP/p300 coactivator interface suppresses hypoxia signaling in Caki-1 renal carcinoma cells
Through a computationally guided virtual screening and molecular dynamics approach, researchers identified the natural-product-like compound SIHC926 as a potent inhibitor of the HIF-1α–CBP/p300 interface that effectively suppresses hypoxia signaling and reduces viability in Caki-1 renal carcinoma cells.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Deep within the human body, cells constantly monitor the air they breathe. When oxygen levels drop, a master switch inside the cell flips on, triggering a survival program that helps the tissue adapt to the low-oxygen environment. This switch is a protein called HIF-1. Under normal conditions, the body keeps this switch turned off, but in certain cancers, the switch gets stuck in the "on" position. This forces the cancer to build new blood vessels and change its metabolism to keep growing, even when oxygen is scarce. To turn this switch on, HIF-1 must physically grab onto a helper protein, a molecular partner that acts like a co-pilot to start the genetic instructions. If scientists could find a way to stop HIF-1 from grabbing this partner, they might be able to shut down the cancer's survival program without harming healthy cells.
A team of researchers at King Khalid University in Saudi Arabia has taken a significant step toward finding such a blocker. They focused on the specific spot where HIF-1 latches onto its helper, a region known as the interface. For years, scientists believed this type of connection was too smooth and featureless to be stopped by a small drug molecule. However, recent advances suggest that these surfaces have small, hidden pockets where a drug could wedge itself in. The researchers set out to find a molecule that could fit into this pocket on the helper protein, effectively crowding out HIF-1 and breaking the connection.
To find a candidate, the team did not start with a physical lab bench but with a powerful computer. They built a digital model of the helper protein's surface and scanned a massive library of about 250,000 different natural-product-like compounds. Imagine sifting through a vast digital warehouse of chemical structures to find the single one that fits a specific lock. The computer ranked these compounds based on how well they seemed to fit the pocket. One molecule, named SIHC926, emerged as the top contender. The researchers then ran a detailed computer simulation lasting 100 nanoseconds to see if this molecule would stay in place or drift away. The simulation showed that SIHC926 remained firmly lodged in the predicted pocket, forming stable connections with the protein's surface.
With a promising digital candidate in hand, the team moved to the laboratory to test if it worked in the real world. They first tested the molecule on a purified version of the helper protein in a test tube. The results were encouraging: SIHC926 successfully stopped HIF-1 from attaching to the helper. In fact, it was more effective at this specific task than YC-1, a known drug used for comparison, requiring a lower concentration to achieve the same level of inhibition. The researchers then moved to living cells, specifically a type of kidney cancer cell known as Caki-1. When these cells were placed in a low-oxygen environment to mimic a tumor, they normally activate their survival genes. However, when treated with SIHC926, this genetic activity dropped significantly. The cells also produced less of a protein called VEGF, which is responsible for building new blood vessels, a key way tumors feed themselves.
The effects of the molecule went beyond just stopping the genetic switch. The treated cancer cells began to die off at a faster rate than untreated cells, showing signs of programmed cell death and an increase in harmful internal oxidation. The concentration needed to kill half of the cancer cells was roughly 2.29 micromolar, which is a very small amount, suggesting the molecule is quite potent. While the molecule performed better than the comparison drug in these specific tests, the researchers were careful to note that this does not yet mean it is a cure. The study was designed as an initial proof of concept, showing that a computer-designed molecule can physically interfere with this specific protein interaction and cause cancer cells to struggle.
Despite these promising results, the authors emphasize that much work remains. The experiments were conducted on a single type of kidney cancer cell, and the molecule has not yet been tested in animals or humans. Furthermore, while the computer models and test-tube experiments strongly suggest the molecule binds to the intended target, direct proof of this binding inside a living human cell is still needed. The researchers also noted that the molecule's ability to kill cells might be partly due to general toxicity rather than just its specific action on the HIF-1 switch. Nevertheless, this work provides a concrete starting point. It demonstrates that the HIF-1 survival switch is vulnerable to small molecules and offers a specific chemical structure, SIHC926, that scientists can now refine and test further. If future studies confirm its safety and specificity, this approach could lead to a new class of drugs that starve tumors by cutting off their oxygen-sensing lifeline.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.